Method for treating and preventing secondary hyperparathyroidism
AssigneeBone Care International, Inc.
InventorsJoyce C. Knutson, Charles W. Bishop, Richard B. Mazess
Life of this patent
Estimating the term…
Abstract
A method for preventing loss of bone mass or bone mineral content in a human being suffering from secondary hyperparathyroidism by administering a sufficient amount of 1.alpha.-OH vitamin D.sub.2, 1.alpha.,24(S)-(OH).sub.2 vitamin D.sub.2, 1.alpha.-OH vitamin D.sub.4 or 1.alpha.,24(R)-(OH).sub.2 vitamin D.sub.4.
Claims9
A method for lowering or maintaining lowered serum parathyroid hormone in human patients suffering from hyperparathyroidism secondary to end stage renal disease, comprising:
- administering to said patients an effective amount of a vitamin D analog to lower and maintain lowered serum parathyroid hormone levels, said analog comprising formula (I):
- ##STR2## wherein B and C are either hydrogen or a carbon-carbon double bond between C.sub.22 and C.sub.23 ;
- and R.sub.1 is hydrogen or hydroxyl provided that when B and C are a double bond, R.sub.1 is hydrogen.
A method of treating a human to alleviate or prevent the pathological effects of hyperparathyroidism secondary to end stage renal disease, wherein the method comprises administering orally to said human, in need thereof, a vitamin D analog selected from the group consisting of 1.alpha.-OH-vitamin D.sub.2 ;
- 1.alpha.-OH-vitamin D.sub.4 ;
- and 1.alpha.,24(R)-(OH).sub.2 -vitamin D.sub.4 wherein said compound is administered to said human in an amount sufficient to lower serum parathyroid hormone levels as measured by blood serum level of parathyroid hormone over time after ingestion in said human to thereby alleviate or prevent said effects.
Dependencies are inferred from the claim text.